A Phase Ib/IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose, Parallel-Group Study To Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ro7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer’s Disease (NCT04639050)
BRAINSHUTTLE
This trial is Currently recruiting
Registration number NCT04639050
Program & service
This trial is being run with the Brain service, and as part of the Neurology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Associate Professor David Darby
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.